Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.18)
# 449
Out of 5,141 analysts
90
Total ratings
52.31%
Success rate
16.12%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Maintains: In-Line | $28 → $35 | $49.87 | -29.82% | 7 | Feb 17, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $779.67 | +12.23% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $21.50 | +86.05% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $25.88 | +112.52% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $27.59 | +26.86% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $11.11 | +125.02% | 1 | Nov 20, 2025 | |
| UPB Upstream Bio | Initiates: Outperform | $40 | $8.08 | +395.05% | 1 | Nov 18, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $60 → $80 | $67.94 | +17.75% | 1 | Sep 3, 2025 | |
| VIR Vir Biotechnology | Initiates: Outperform | $12 | $7.56 | +58.73% | 1 | Sep 3, 2025 | |
| SMMT Summit Therapeutics | Maintains: Outperform | $30 → $34 | $15.94 | +113.30% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $42.23 | +30.24% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $128.63 | +43.82% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $68.14 | -26.62% | 3 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $50 | $29.31 | +70.59% | 2 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $110.15 | +13.49% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $64.08 | +63.86% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $85 | $64.11 | +32.58% | 1 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $22.72 | +287.32% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $192.03 | +43.73% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $4.01 | +772.82% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $374.75 | -38.09% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $101.32 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $151.40 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $31.91 | -34.19% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.83 | +236.75% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.47 | +580.27% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.80 | - | 5 | Feb 14, 2018 |
Moderna
Feb 17, 2026
Maintains: In-Line
Price Target: $28 → $35
Current: $49.87
Upside: -29.82%
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $779.67
Upside: +12.23%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $21.50
Upside: +86.05%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $25.88
Upside: +112.52%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $27.59
Upside: +26.86%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $11.11
Upside: +125.02%
Upstream Bio
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $8.08
Upside: +395.05%
Cytokinetics
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $67.94
Upside: +17.75%
Vir Biotechnology
Sep 3, 2025
Initiates: Outperform
Price Target: $12
Current: $7.56
Upside: +58.73%
Summit Therapeutics
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $15.94
Upside: +113.30%
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $42.23
Upside: +30.24%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $128.63
Upside: +43.82%
Dec 23, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $68.14
Upside: -26.62%
Dec 17, 2024
Maintains: Outperform
Price Target: $45 → $50
Current: $29.31
Upside: +70.59%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $110.15
Upside: +13.49%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $64.08
Upside: +63.86%
May 14, 2024
Initiates: Outperform
Price Target: $85
Current: $64.11
Upside: +32.58%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $22.72
Upside: +287.32%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $192.03
Upside: +43.73%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $4.01
Upside: +772.82%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $374.75
Upside: -38.09%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $101.32
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $151.40
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $31.91
Upside: -34.19%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.83
Upside: +236.75%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.47
Upside: +580.27%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $10.80
Upside: -